+ Watch NAVB
on My Watchlist
"old-timers" mapping process...
With the recent C-code approval as well as a full quarters worth of lymphoseek profits, this stock is poised for a huge run up. It is already drastically undervalued and with a solid pipeline working its way through fda approval. A 5-6 dollar share price by the new year is completely feasible.
Revenue just started to stream
Has the potential to rise a few cents and that is it
PDUFA coming up
Lymphoseek clinical data was outstanding, with a spotless safety profile. Current mapping agents have significant drawbacks. The company also has RIGScan CR coming back to clinical trials, and is adding a third drug to their pipeline in Q4 or Q1/2012. This could be an up and coming specialty pharma play.
As of 10/19/11, Neoprobe's New Drug Application (NDA) for Lymphoseek® (tilmanocept) has been accepted for review by the FDA.
bet for stock option
Extremely overvalued trash stock.
I like the recent insider buying.
they have a great product and another product in development
Lymphoseek has passed two separate phase 3 trials, showing superiority over the drug (blue dye) currently used to detect cancer. There's 450 million right there if they charge the same price as blue dye, but they will charge more if the FDA does in fact give it to the superior label. Their next drug, which is actually their oldest drug, RigScan CR, has an estimate of 3 Billion. They will use the revenue from Lymphoseek and possibly partner with another company to develop this huge drug.
The pipeline of lymphoseek and RIGS coming to the market will make this a double in 2012
They are on track w/Lymphoseek, a game changer in the diagnosis of cancer.
1) Lymphoseek has had no safety events2) Fully funded through the NDA3) Management now has experience4) Multiple pre-NDA meetings with FDA5) Pre-approval negotiated distribution deal in place
very speculative, can be 10 end of the year if everything goes well.
http://neoprobe.com/studies/RIGSBio.pdf"RIGS is identifying important new tissues that we have not been capable of identifying before" To serve our patients better, we as physicians and surgeons need to shift our reliance on an old paradigm of defining cancer as a crisis of cellular morphology to a new paradigm of recognizing the tumor as a systemic manifestation of a dangerous cascade of cellular and biological events. Localizing the disease and cytoreducing it works only to a point. We have reached that point and must move beyond it."In my talks with Brent, he discussed how Avastin (a blockbuster drug by the way) has minimal impact on survival. Yet RIGS scan looks to provide a dramatic overall improvement in cancer therapy in relation.I also discussed lymphoseek, and shared my enthusiasm for a product that can reduce down time in nuclear medicine. The latest board activity from fellow nuclear techs(We have a community site sharing thoughts on anything clinically applicable to nuclear medicine) has generated many hits on current sulfur colloid combined with lidocaine to reduce pain. From what I gather lymposeek seems to be associated with less pain at injection site, which also seems to be speaking to nuclear medicine community concerns with colloidal agents. Although anecdotal, opinions I'm hearing is 65% of all SNLB is being performed with current radio labeled colloidal agents. I'm thinking end game here is buyout, and wouldn't be surprised to see this happen later this year with SPA and satisfactory statistical endpoints to be met, to clarify regulatory approval of RIGS technology. I would be shocked if Cardinal health is not either a buyer of Neoprobe or the commercial partner of RIGS technology. Neoprobe is just a few blocks from Cardinal headquarters, and I am told CEO Bupp, and Cardinal big wigs socialize on the golf course. Also seems Cardinal is being represented in new hires of late. One in particular has merger and acquisition experience at Cardinal. http://finance.yahoo.com/news/Neoprobe-Nominates-Brendan-bw-1056225873.html?x=0&.v=1http://www.cardinal.com/content/news/8132007_135242.aspEric Rowinsky looks to be a recent Carl Icahn nominee for Biogen http://www.euroinvestor.fr/news/story.aspx?id=10950606&bw=20100322005794
Wow, picked this one just for the heck of it. They sport a $119M market cap, while their assets are $9,017,759 and have negative revenues. They have a totally deserving market cap, unlike most other OTCBB stocks! Their liabilities and stockholder defecit (That's where stockholder equity should be!) is ($9,017,759). Good accounting! Their debts don't exceed their assets! They have negative earnings, too (No surprise there!). This one is going down to $0.00!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions